Page 6 - Nautilus Platform News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Nautilus platform. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Nautilus Platform Today - Breaking & Trending Today

-$0.17 Earnings Per Share Expected for Nautilus Biotechnology, Inc. (NASDAQ:NAUT) This Quarter

Equities analysts expect Nautilus Biotechnology, Inc. (NASDAQ:NAUT – Get Rating) to announce earnings of ($0.17) per share for the current quarter, Zacks reports. Zero analysts have made estimates for Nautilus Biotechnology’s earnings, with the highest EPS estimate coming in at ($0.15) and the lowest estimate coming in at ($0.18). Nautilus Biotechnology reported earnings per share […] ....

Sujalm Patel , Nautilus Biotechnology Inc , Securities Exchange Commission , Goldman Sachs Group Inc , Mirabella Financial Services , Tikvah Management , Zacks Investment Research , Goldman Sachs Group , Nautilus Biotechnology , Get Rating , Investment Research , Exchange Commission , Financial Services , Street Group , Sachs Group , Nautilus Platform , Nasdaq Naut ,

Nautilus Biotechnology (NAUT) Set to Announce Earnings on Tuesday

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) is scheduled to be releasing its earnings data before the market opens on Tuesday, May 3rd. Analysts expect Nautilus Biotechnology to post earnings of ($0.15) per share for the quarter. Parties that are interested in registering for the company’s conference call can do so using this link. Nautilus Biotechnology […] ....

Thomson Reuter , Sujalm Patel , Morgan Stanley , Nautilus Biotechnology Inc , Geode Capital Management , Goldman Sachs Group Inc , Virtu Financial , Zacks Investment Research , Blackrock Inc , Goldman Sachs Group , Nautilus Biotechnology , Get Rating , Investment Research , Street Corp , Sachs Group , Capital Management , Nautilus Platform , Nasdaq Naut ,

Nautilus Biotechnology (NASDAQ:NAUT) Downgraded by Zacks Investment Research to "Sell"

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a research report issued on Saturday, Zacks.com reports. According to Zacks, “Nautilus Biotechnology Inc. is a development stage life sciences company creating a platform technology for quantifying and unlocking the complexity of the proteome. […] ....

Sujalm Patel , Morgan Stanley , Nautilus Biotechnology Inc , Arya Sciences Acquisition Corp , Securities Exchange Commission , Tikvah Management , Zacks Investment Research , Perceptive Advisors , Blackrock Inc , Affinity Asset Advisors , Franklin Resources Inc , Goldman Sachs Group , Nautilus Biotechnology , Get Rating , Biotechnology Inc , Exchange Commission , Asset Advisors , Nautilus Platform , Nasdaq Naut ,

Nautilus Biotechnology (NASDAQ:NAUT) Given New $5.00 Price Target at The Goldman Sachs Group

Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) had its price target dropped by stock analysts at The Goldman Sachs Group from $9.00 to $5.00 in a research report issued to clients and investors on Wednesday, Benzinga reports. The brokerage currently has a “neutral” rating on the stock. The Goldman Sachs Group’s price target would suggest a […] ....

Sujalm Patel , Morgan Stanley , Qube Research Technologies Ltd , Nautilus Biotechnology Inc , Securities Exchange Commission , Goldman Sachs Group Inc , Zacks Investment Research , Investment Advisers , Jpmorgan Chase Co , Goldman Sachs Group , Raymond James Associates , Nautilus Biotechnology , Get Rating , Investment Research , Exchange Commission , Technologies Ltd , Sachs Group , Nautilus Platform , Nasdaq Naut , Lower Price Target , The Goldman Sachs Group Inc ,

Contrasting Avantor (NYSE:AVTR) & Nautilus Biotechnology (NASDAQ:NAUT)

Avantor (NYSE:AVTR – Get Rating) and Nautilus Biotechnology (NASDAQ:NAUT – Get Rating) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, valuation, dividends, analyst recommendations and risk. Analyst Recommendations This is a breakdown of recent recommendations and price […] ....

United States , Nautilus Biotechnology Inc , Avantor Inc , Get Rating , Nautilus Biotechnology , Given Nautilus Biotechnology , Middle East , Nautilus Platform , Nyse Avtr , Stock Comparison , Stock Analysis ,